However, in a Phase 1/2 trial of tipifarnib, an orally available FTI, in combination with preoperative doxorubicin and cyclophosphamide in 22 HER2− IBC patients, showed that only one patient achieved pCR [112]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.